Eleven-Year surveillance of methicillin-resistant Staphylococcus aureus infections at an Academic Health Centre

SAFIYA AL MUSAWI1, QASSIM ALKHALEEFA2, SAMIA ALNASSRI1, AISHA M ALAMRI1, AMANI ALNIMR2

1 Department of Pathology, Salmaniya Medical Complex, Ministry of Health, Kingdom of Bahrain; 2 Department of Microbiology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia; 3 Department of Infection Control, King Fahad Hospital of the University, Dammam, Kingdom of Saudi Arabia; 4 Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia

Key words
Staphylococcus aureus • Infection • Methicillin-Resistant

Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is an important human pathogen associated with nosocomial and community infections. There is a continual focus on the epidemiology of this public health threat owing to the increase in its spread and rapid development of resistance.

Aim. We aimed to demonstrate the time trend of antibiotic resistance by describing the epidemiology of MRSA infections at an academic health centre.

Methodology. We retrospectively reviewed cases during an 11-year period (from January 2009 to December 2019) with positive cultures for MRSA from various clinical sites in King Fahad Hospital of the University, to understand their clinical and microbiological profiles. Screening and colonisation samples were excluded.

Results. A total of 1338 MRSA isolates were identified, with an increasing trend from 5.2% to 14.5% during 2009-2019. Skin and soft tissue samples were the most common source (52.4%) of MRSA infections. Vancomycin activity remained stable against MRSA, and only one isolate showed resistance to linezolid (< 1%). A significant reduction in susceptibility to clindamycin (p = 0.003), trimethoprim-sulfamethoxazole (p = 0.001), and rifampin (p < 0.0001) was detected over the study period.

Conclusions. MRSA infections still represent a significant burden on healthcare systems. Our data support the need for constant local and regional surveillance to devise relevant protocols to manage MRSA infections. Empirical therapy needs to consider the changing antimicrobial susceptibility trends among MRSA isolates.

Methods

Study settings
This was a retrospective, cross-sectional study at King Fahad Hospital of the University (KFHU) Al-Khobar, a
550-bed secondary care and academic training facility. Culture-positive MRSA samples representing infections, obtained from various sites between January 2009 and December 2019 in patients of all age groups, were included. Cases with clinically significant isolates were identified by reviewing electronic charts individually, eliminating screening samples for colonisation sites. Patients’ data (sex, age, and location of patients when specimens were collected) and microbiological results from the laboratory information system were analyzed for the included cases. Routine testing of MRSA isolates in the laboratory was performed using the VITEK 2 automated system (bioMérieux Inc., Durham, NC, USA) between 2009 and 2016 and the VITEK MS (bioMérieux Inc.) between 2017 and 2019. Cefoxitin 30 µg discs on Muller-Hinton agar (SPML, Dammam, Saudi Arabia) were used to screen for MRSA, followed by susceptibility testing using the VITEK 2 automated system throughout the study period. The results were interpreted based on the Clinical & Laboratory Standards Institute (CLSI) breakpoints [14]. Any discrepancy between the cefoxitin inducer test and VITEK 2 system was resolved by molecular testing (GeneXpert MRSA). Patients with repeated MRSA positive culture result within 6-month period were excluded in the analysis.

**Statistical analysis**

Statistical analysis was performed using version 23.0 of the Statistical Package for Social Sciences (IBM Corp., Armonk, NY, USA). The Pearson chi-square test was applied to measure the proportion difference, and a p-value < 0.05 was considered statistically significant.

**Results**

**Demographic profile**

A total of 1338 MRSA isolates were included during the study period, of which 138 (10.3%) were from the intensive care unit (ICU). Demographic data of the patients are summarised in Table I. Over the 11-year study period, there was an increase in the absolute number of MRSA cases from 5.2% in 2009 to 14.5% in 2019. In 2010, there was a reduction in MRSA cases (4.8%) compared to the other years. A large proportion of the patients (n = 324, 24.2%) were aged < 1-9 years, with an overall female to male ratio of 1:1.17. Figure 1 illustrates the number of MRSA cases per sex over the study period, and Figure 2 highlights the age trend of MRSA over the years.

**Distribution of MRSA in different clinical samples**

Skin and soft tissue specimens were found to be the major source of MRSA cases (52.4%; n = 702) in the cohort, followed by lower respiratory specimens (15.1%; n = 203). Lower respiratory specimens were the dominant source of MRSA infections in the ICU (71.7%; n = 99). Table II shows the distribution of MRSA among the different types of clinical specimens.
**ANTIBIOTIC SUSCEPTIBILITY PATTERN**

Overall, the MRSA isolates were highly susceptible to glycopeptides, oxazolidinone, and rifampin (Tab. III). In contrast, moderate susceptibility was noted for lincosamides and sulfonamides, and low sensitivity rates were noted for macrolides. The linezolid-resistant strain was isolated from an 80-year-old Filipino male patient who presented with a left forearm abscess. Confirmatory linezolid E-test was performed for this strain, which showed a minimal inhibitory concentration (MIC) \( > 256 \) µg/mL. This isolate was also resistant to clindamycin and chloramphenicol but retained susceptibility to sulfonamides. Moreover, the resistance rate to erythromycin (31.7%) was high, followed by that to clindamycin (26.4%). Of the 137 erythromycin-resistant MRSA isolates, 81%, 32.8%, and 8% were also resistant to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, respectively. There was a significant reduction in clindamycin \((p = 0.003)\), trimethoprim-sulfamethoxazole \((p = 0.001)\), and rifampin \((p < 0.0001)\) susceptibility over the years. However, no significant difference was noted in the susceptibility to erythromycin over time \((p = 0.167)\) (Fig. 3).

**Discussion**

The global epidemiology of MRSA infection in community and healthcare settings has evolved rapidly in recent years [1-3]. In Saudi Arabia, the prevalence of MRSA varies widely, ranging from 2 to 38% [11, 15, 16]. In our study, MRSA isolate numbers showed an increasing trend from 5.2% in 2009 to 14.5% in 2019. Approximately 24% of MRSA isolates in this study were from patients aged \(< 1\) years. In the United States and Canada, the clinical epidemiology and molecular characteristics of MRSA infections in the paediatric age group changed dramatically between 2000 and 2010. This was owing to an epidemic of community-associated MRSA skin and soft tissue infections (SSTIs) and the introduction of the USA300 pulsed-field gel electrophoresis typing of MRSA in the healthcare and community settings [17]. MRSA was previously shown to be distributed differently in different age groups. In two local studies, MRSA isolates were found in the extreme age groups of patients who were \( \geq 60\) and \( \leq 5\) and \( \leq 1\) years old [13, 18]. Another study showed that patients aged 56 years and older had the highest prevalence of MRSA [10]. In the United States, one study found a trend of declining age over a 10-year period of observation, while another study at the same time showed that greatest increase in MRSA rate was in people aged \( \leq 17\) years [13, 19]. These observations clearly indicate the variations based on geographical location. Regarding gender distribution, 54% of the isolates were recovered from male patients, while 46% were from females. Other studies have also shown that MRSA isolates were recovered relatively more from males than females in Saudi Arabia [18, 20, 21].

Skin and soft tissue infections were the most common infections caused by MRSA in the present study, in concordance with the established evidence from a number of studies [10, 22-24]. In a US study conducted between 1996 and 2006, Frei et al. discovered 58,942 MRSA infection cases (9.6%) from clinical infections in the skin and soft tissue of paediatric patients [22]. As stated by the CDC, 33% of humans have *S. aureus* in their nose and approximately 2 in every 100 have MRSA. One of the main limitations of this study was that the screening and colonization samples were excluded. Despite the fact that many people are MRSA nasal carriers, the majority do not develop serious MRSA infections [25]. However, nasal and skin carriage of *S. aureus* have been reported as a potential source of infected skin and soft tissue [26, 27]. In our study, lower respiratory samples were the most common site of MRSA in the ICU, in contrast to that in other studies where blood stream infections were the most common site of ICU-related MRSA infections [28, 29]. MRSA infections of the skin and soft tissues, as well as pneumonia, may cause bloodstream infections and are linked to higher mortality rates, higher hospital costs, and longer hospital stays than infections caused by methicillin-susceptible *S. aureus* isolates [21, 30, 31]. In the current study, 6.9% of MRSA isolates originated from the blood. MRSA bacteremia is a serious, life-threatening infection with an estimated mortality rate of
20-40% [32, 33]. According to the 2014 World Health Organization Antimicrobial Resistance Report, MRSA represents a widely variable proportion (20-80%) of cases of staphylococcal bacteraemia [34]. Several antimicrobial therapies are available for the treatment of MRSA infections. However, numerous publications, including the 2019 antibiotic resistance threats report by the CDC, demonstrate that MRSA has become resistant to many first-line antibiotics [2, 3, 25]. In the current study, all MRSA isolates were susceptible to vancomycin. Similar results have been reported in several other local studies [10, 23, 24]. Several countries have reported clinical strains of *S. aureus* with reduced susceptibility to vancomycin after the appearance of the first case in Japan [35-37]. In 2010, the first detected MRSA strain (D958) with reduced susceptibility to vancomycin was reported in Saudi Arabia [38]. While MRSA with reduced vancomycin susceptibility has not been identified at our institution, the unique ability of *S. aureus* to acquire resistance necessitates the use of surveillance programs to combat this problem. In the present study, in line with previous studies, one MRSA strain (0.1%) was reported to be resistant to linezolid [13, 39, 40]. The phenotype exhibited by the strain is suggestive of the rare *cfr* methyltransferase mechanism that confers resistance to erythromycin, clindamycin, chloramphenicol, and linezolid; however, this is uncertain since the isolate was not available for molecular characterisation at the time of the study. Staphylococcal resistance to linezolid is uncommon and is usually mediated by the G2576T point mutation related to the 23S rRNA binding site DOMAIN V [41]. Regarding the other antimicrobial agents, a significant reduction in the susceptibility to clindamycin, trimethoprim-sulfamethoxazole, and rifampin was noted over the years. A recently published large global surveillance study showed that these antimicrobial agents exhibited increased resistance over time, which is consistent with our findings [42]. Variations observed in the susceptibility of MRSA isolates over the years and the geographical variation and diversity in susceptibility...
patterns necessitate continuous local and regional surveillance in order to devise comprehensive protocols. Although MRSA is traditionally classified as healthcare-associated (HA-MRSA) and community-associated (CA-MRSA), this classification also overlaps at the molecular and epidemiological levels [43]. Thus, the Disease Control and Prevention Active Bacterial Core (CDC-ABC) Surveillance System recommends subdividing HA-MRSA based on the setting of onset: hospital or community [44]. A limitation of our study is that we were unable to retrospectively differentiate between community- and hospital-acquired MRSA infections. A published study from Saudi Arabia showed an increasing proportion of community-acquired MRSA infections from 41.7% in 1999 to 66.6% in 2002, and reduced nosocomial MRSA infection from 33% in 1999 to 19% in 2003 [12]. According to a cross-sectional study published by KFHU from January 2010 to September 2011, SCCmec type IV was the most frequently found genotype in a total of 106 MRSA isolates from infection and carrier colonisation sites. This shows that most strains were of community origin [45].

Conclusions

With the help of the present study, we inferred that skin and soft tissue are the primary sources of MRSA at King Fahad Hospital of the University (KFHU) in Al-Khobar, Saudi Arabia. Throughout the 11-year study period, the trend of MRSA infections has increased with the emergence of new strains that showed resistance to one or more antibiotic classes. These findings highlight the need for continuous surveillance to understand microbial infections, their antibiotic resistance patterns, and to identify the emergence of new strains for successful management and control.

Ethical approval

Ethical approval for this study was obtained from the Institutional Review Board of Imam Abdulrahman Bin Faisal University (IRB-PGS-2020-01-368).

Acknowledgements

The authors would like to thank all personnel working in the Diagnostic Microbiology Laboratory and Infection Control department at KFHU who were involved in the routine processing of data related to this project.

Consent for publication

Not applicable.

Availability of data and material

Data available on request from the authors.

Conflict of interest statement

No conflict of interest to disclose that is relevant to this study.

Funding

No funding was received for this work.

Authors’ contributions

A.A. and S.A.L. conceived of the presented idea conceptualization. A.A. and A.M.A designed the investigational methodology. S.A.M., Q.A. and S.A.L performed the collection and formal analysis of the data. S.A.M. wrote the manuscript. A.A. and A.M.A supervised the project administration. All authors reviewed and approved the final manuscript.

References

[1] Antibiotic resistance threats in the United States, 2019 [Internet]. Centers for Disease Control and Prevention. 2019 [cited 19 April 2021]. Available from: https://doi.org/10.15620/cdc.82532

[2] Monaco M, Pimentel de Araujo F, Cruciani M, Coccia EM, Pantosti A. Worldwide epidemiology and antibiotic resistance of Staphylococcus aureus. Curr Top Microbiol Immunol 2016;409:21-56. https://doi.org/10.1007/82_2016_3

[3] Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010;51(S2):S183-S197. https://doi.org/10.1086/653519

[4] Eriksen K, Erichsen I. Resistance to methicillin, isoxazolyl penicillins, and cephalothin in staphylococcus aureus. Acta Pathol Microbiol Scand 1964;62:255-75. https://doi.org/10.1111/apm.1964.62.2.255

[5] Pada S, Ding Y, Ling M, Hsu L, Earnest A, Lee T, Pada SK, Ding Y, Ling ML, Hsu LY, Earnest A, Lee TE, Yong HC, Ju-reen R, Fisher D. Economic and clinical impact of nosocomial meticillin-resistant Staphylococcus aureus infections in Singapore: a matched case-control study. J Hosp Infect 2011;78:36-40. https://doi.org/10.1016/j.jhin.2010.10.016

[6] Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010;23:99-139. https://doi.org/10.1128/CMR.00042-09

[7] van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54:755-71. https://doi.org/10.1093/cid/cir395

[8] Yezli S, Shibil AM, Livermore DM, Memish ZA. Antimicrobial resistance among Gram-positive pathogens in Saudi Arabia. J Chemother 2012;24:125-36. https://doi.org/10.1179/1973947812Y.0000000010

[9] Aly M, Balkhy HH. The prevalence of antimicrobial resistance in clinical isolates from Gulf Corporation Council countries. Antimicrob Resist Infect Control 2012;1:26. https://doi.org/10.1186/2047-2994-1-26

[10] El Amin NM, Faidah HS. Methicillin-resistant Staphylococcus aureus in the western region of Saudi Arabia: prevalence and
antibiotic susceptibility pattern. Ann Saudi Med 2012;32:513-6. https://doi.org/10.5144/0256-4947.2012.513

[11] Al-Yousef SA, Mahmoud SY, Taha EM. Prevalence of methicillin-resistant Staphylococcus aureus in Saudi Arabia: systemic review and meta-analysis. Afr J Clin Exp Microbiol 2013;14:146-54. https://doi.org/10.4314/ajcem.v14i3.5

[12] Al-Tawfiq JA. Incidence and epidemiology of methicillin-resistant Staphylococcus aureus Infection in a Saudi Arabian Hospital, 1999-2003. Infect Control Hosp Epidemiol 2006;27:1137-9. https://doi.org/10.1086/507971

[13] Baddour MM, Abuelkheir MM, Fatani AJ. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann Clin Microbiol Antimicrob 2006;5:30. https://doi.org/10.1186/1476-0711-5-30

[14] CLSI. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. CLSI document M100-19. Wayne, PA: Clinical and Laboratory Standards Institute 2009.

[15] Madani TA. Epidemiology and clinical features of methicillin-resistant Staphylococcus aureus in the University Hospital, Jeddah, Saudi Arabia. Can J Infect Dis 2002;13:245-50. https://doi.org/10.1155/2002/235213

[16] Austin TW, Austin MA, McAlear DE, Coleman BT, Osoba AO, Thaqafi AO, Lamfon MA. MRSA prevalence in a teaching hospital in Western Saudi Arabia. Saudi Med J 2003;24:1313-6. PMID: 14710275

[17] David MZ, Daum RS. Update on epidemiology and treatment of MRSA Infections in Children. Curr Pediatr Rep 2013;1:170-81. https://doi.org/10.1007/s13222-012-0023-7

[18] Van Belkum A, Vandenbergh M, Kessie G, Qadri SM, Lee G, Van Den Braak N, Verbrugh H, al-Ahdal MN. Genetic heterogeneity among meticillin-resistant Staphylococcus aureus strains from Saudi Arabia. Microb Drug Resist 1997;3:365-9. https://doi.org/10.1089/mdr.1997.3.365

[19] Bordon J, Master RN, Clark RB, Duvvuri P, Karlowsky JA, Ayesu K, Klotchock A, Kapoor R, Ramirez J. Methicillin-resistant Staphylococcus aureus resistance to non-β-lactam antimicrobials in the United States from 1996 to 2008. Diagn Microbiol Infect Dis 2010;67:395-8. https://doi.org/10.1016/j.diagmicrobio.2010.03.006

[20] Madani TA, Al-Abdullah NA, Al-Sanousi AA, Ghabrah TM, Afandi SZ, Bajunid HA. Methicillin-resistant Staphylococcus aureus in two Tertiary-Care Centers in Jeddah, Saudi Arabia. Infect Control Hosp Epidemiol 2001;22:211-6. https://doi.org/10.1086/501891

[21] Bukhari HA, Abdelhadi MS. The epidemiology of methicillin-resistant staphylococcus aureus infections at a Saudi University Hospital. Microb Drug Resist 2001;7:413-6. https://doi.org/10.1089/10766290152773428

[22] Frei C, Makos B, Daniels K, Omaromiancu C. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. J Pediatr Surg 2010;45:1967-70. https://doi.org/10.1016/j.jpedsurg.2010.05.009

[23] Almanaa TN, Alyahya SA, Khaled JM, Shehu MR, Alharbi NS, Kadaikunnan S, Alboaidi AS, Khalid Alzahrani A. The extreme drug resistance (XDR) Staphylococcus aureus strains among patients: a retrospective study. Saudi J Biol Sci 2020;27:1985-92. https://doi.org/10.1016/j.sjbsa.2020.04.003

[24] Al-Hamad AM, Alfajri AA, Altowaisleb J, Al-Shamani SM, Leskafti H, Alsubaikehy FA, Abbas HR. Incidence and antibiotic susceptibility of MRSA infections in a Saudi Arabian Hospital: a 10-year surveillance study. J Infect Dev Ctries 2018;12:454-61. https://doi.org/10.3855/jidc.9778

[25] Healthcare Settings | MRSA | CDC [Internet]. Cdc.gov. 2019 [cited 19 April 2021]. Available from: https://www.cdc.gov/mrsa/healthcare/index.html

[26] Wenzel R, Perl T. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13-24. https://doi.org/10.1016/0195-6701(95)90079-9

[27] Hauser C, Wuehrich B, Matter L, Wilhelm JA, Sonnabend W, Schopfer K. Staphylococcus aureus skin colonization in atopic dermatitis patients. Dermatologica 1985;170:35-9. PMID: 3972149

[28] Oztropnak N, Cevik MA, Akinci E, Korkmaz M, Erbay A, Eren SS, Balaban N, Bodur H. Risk factors for ICU-acquired methicillin-resistant Staphylococcus aureus infections. Am J Infect Control 2006;34:1-5. https://doi.org/10.1016/j.ajic.2005.07.005

[29] Ali MA, Rajab AM, Al-Khani AM, Ayash SQ, Basha AC, Abdelgadir A, Rajab TM, Enabi S, Saqib N. Methicillin-resistant Staphylococcus aureus development in intensive care patients. Saudi Med J 2020;41:1181-6. https://doi.org/10.15537/smj.2020.11.25465

[30] Otto M, Chatterjee SS. Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves. Clin Epidemiol 2013;5:205-17. https://doi.org/10.2147/CLEP.S37071

[31] Kaye KS, Engemann JJ, Moazzafari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004;10:1125-8. https://doi.org/10.3201/eid1006.020665

[32] Mylotte JM, McDermott C, Spooner JA. Prospective Study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Clin Infect Dis 1987;9:891-907. https://doi.org/10.1093/clinids/9.5.891

[33] Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007;28:273-9. https://doi.org/10.1086/515267

[34] Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization 2014.

[35] Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, Fukuchi Y, Kobayashi I. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3. https://doi.org/10.1016/S0140-6736(97)90324-8

[36] Fridkin SK, Hageman J, McDougal LK, Mohammed J, Jarvis WR, Perl TM, Tenover FC. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003;36:429-39. https://doi.org/10.1086/346207

[37] Geisel R, Schmitz FJ, Fluit AC, Labischinski H. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2001;20:685-97. https://doi.org/10.1007/s10096-001-00595

[38] Al-Obeid S, Haddad Q, Cherkaoui A, Schrenzel J, Francois P. First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia. J Clin Microbiol 2010;48:2199-204. doi: 10.1128/JCM.00954-09

[39] Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wenersten C, Venkataraman L, Moellering RC, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8. https://doi.org/10.1016/S0140-6736(01)50410-1

[40] Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Peláez B, Andrade R, De la Torre MA, Fereres J, Sánchez-Garcia M. Resistance to linezolid is mediated by the gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50:821-5. https://doi.org/10.1086/650574

[41] Seke Etef PF, Nwabo Kamidje AH, Vecchio L, Farahna M, Ma-homoodally MF. In: Kon K, Rai MBT-AR, eds. Chapter 3: Signalling pathways sustaining antibiotic resistance: lessons from methicillin-resistant Staphylococcus aureus. Academic Press
[42] Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-year trends in antimicrobial susceptibilities among staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis 2019;6(Suppl. 1):S47-S53. https://doi.org/10.1093/ofid/ofy270

[43] Miller LG, Perdreau-Remington F, Bayer AS, Diep B, Tan N, Bharadwa K, Taux J, Perlroth J, Shay A, Tagudar G, Ibebuogu U, Spellberg B. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007;44:471-82. https://doi.org/10.1086/511033

[44] Tracking Staph Infections | HAIC Activities | HAI | CDC [Internet]. Cdc.gov. 2021 [cited 5 June 2021]. Available from: https://www.cdc.gov/hai/eip/saureus.html

[45] Alkharsah K, Rehman S, Alkhamis F, Alnimr A, Diab A, Al-Ali A. Comparative and molecular analysis of MRSA isolates from infection sites and carrier colonization sites. Ann Clin Microbiol Antimicrob 2018;17:7. https://doi.org/10.1186/s12941-018-0260-2

Received on November 4, 2021. Accepted on December 12, 2021.

Correspondence: Amani Mansour Mohmad Alnimr, Department of Microbiology, College of Medicine, Imam Abdul Rahman Bin Faisal University (IAU), P.O. Box 1982, Dammam 31441, Saudi Arabia - Tel.: +966 56 318 1019 - E-mail: amalnimr@iau.edu.sa

How to cite this article: Al Musawi S, Alkhalefa Q, Alnassri S, Alamri AM, Alnimr A. Eleven-year surveillance of methicillin-resistant Staphylococcus aureus infections at an Academic Health Centre. J Prev Med Hyg 2022;63:E132-E138. https://doi.org/10.15167/2421-4248/jpmh2022.63.1.2387

© Copyright by Pacini Editore Srl, Pisa, Italy

This is an open access article distributed in accordance with the CC-BY-NC-ND (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International) license. The article can be used by giving appropriate credit and mentioning the license, but only for non-commercial purposes and only in the original version. For further information: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en